Abstract:Reactive oxygen species (ROS) are thought to be among the initiating insults that drive carcinogenesis; however, beyond the mutagenic properties of ROS, it is unclear how reactive oxygen species and response to redox imbalance may shape cancer phenotype. We have previously observed that basal activity of the powerfully oncogenic transcription factor NF-κB in cultured breast cancer and other tumor cell lines is dependent upon the DNA damage-responsive kinase ATM. Here we show that, in MDA-MB-231 and HeLa cells, basal ATM-dependent NF-κB activation occurs through a canonical DNA damage-responsive signaling pathway as knockdown of two proteins involved in this signaling pathway, ERC1 and TAB1, results in loss of NF-κB basal activity. We further show that knockdown of ATM in MDA-MB-231, a breast cancer line with a pronounced mesenchymal phenotype, results in the reversion of these cells to an epithelial morphology and gene expression pattern. Culture of MDA-MB-231 and HeLa cells on the antioxidant N-acetyl cysteine (NAC) blunted NF-κB transcriptional activity, and long-term culture on low doses of NAC resulted in coordinate reductions in steady-state ROS levels, acquisition of an epithelial morphology, as well as upregulation of epithelial and downregulation of mesenchymal marker gene expression. Moreover, these reversible effects are attributable, at least in part, to downregulation of ATM-dependent NF-κB signaling in MDA-MB-231 cells as RNAi-mediated knockdown of the NF-κB subunit RelA or its upstream activator TG2 produced similar alterations in phenotype. We conclude that chronic activation of ATM in response to persistent ROS insult triggers continual activation of the oncogenic NF-κB transcriptional complex that, in turn, promotes aggressive breast cancer phenotype.

Cancer cells co-opt the neuronal redox-sensing channel TRPA1 to promote oxidative-stress tolerance

Thioredoxin Activity Confers Resistance Against Oxidative Stress In Tumor-Infiltrating Nk Cells

Reactive Oxygen Species and NRF2 Signaling, Friends or Foes in Cancer?

Vulnerability of Antioxidant Drug Therapies on Targeting the Nrf2-Trp53-Jdp2 Axis in Controlling Tumorigenesis

KEAP1 Is a Redox Sensitive Target That Arbitrates the Opposing Radiosensitive Effects of Parthenolide in Normal and Cancer Cells

The Cancer Antioxidant Regulation System in Therapeutic Resistance

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

Crosstalk between calcium and reactive oxygen species signaling in cancer

Oxidative stress in malignant melanoma enhances tumor necrosis factor-α secretion of tumor-associated macrophages that promote cancer cell invasion.

Mitochondrial Redox Signaling And Tumor Progression

Oxidative Stress and Drug Resistance in Cancer

Oxidative Stress in Cancer Therapy: Friend or Enemy?

Role of Reductive versus Oxidative Stress in Tumor Progression and Anticancer Drug Resistance

A cancer-specific activatable theranostic nanodrug for enhanced therapeutic efficacy via amplification of oxidative stress

Exploring the Thioredoxin System as a Therapeutic Target in Cancer: Mechanisms and Implications

Modulating Intracellular Oxidative Stress Via Engineered Nanotherapeutics

CBD activation of TRPV1 induces oxidative signaling and subsequent ER stress in breast cancer cell lines

RGS5+ lymphatic endothelial cells facilitate metastasis and acquired drug resistance of breast cancer through oxidative stress-sensing mechanism

Control of Oxidative Stress in Cancer Chemoresistance: Spotlight on Nrf2 Role

Modulation of redox signal transduction pathways in the treatment of cancer

Oxidative stress shapes breast cancer phenotype through chronic activation of ATM-dependent signaling